ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
With reference to the captioned subject, please find enclosed herewith the intimation dated 2nd December, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding receipt of the request(s)/application(s) from the registered shareholder(s) of the Company for issue of Duplicate Share Certificate(s).
Alembic Pharma gets USFDA nod for generic drug
The approval by the US Food Drug Administration (USFDA) for the abbreviated new drug application (ANDA) of diclofenac sodium topical solution is for strength of 2 per cent, the company said in a statement. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Diclofenac Sodium Topical Solution USP, 2% w/w. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
With reference to the captioned subject, please find enclosed herewith the intimation dated 27th November, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding receipt of the request(s)/application(s) from the registered shareholder(s) of the Company for issue of Duplicate Share Certificate(s). ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
With reference to the captioned subject, please find enclosed herewith the intimation dated 25th November, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding approval of the request received for issue of Duplicate Share Certificate(s) and issue of letter of confirmation in lieu of the physical share certificate to the registered shareholder(s) and/or their legal heir(s) in accordance with the provisions of SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated 25th January, 2022. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the management of the Company shall be meeting analysts/investors through NBIE Virtual Investor Meeting hosted by Nirmal Bang Institutional Equities on 25th November, 2022. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosures Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the SEBI Listing Regulations, 2015, we enclose herewith Disclosure of Related Party Transactions for the half year ended 30th September, 2022. We request you to kindly take the same on record.
Hold Alembic Pharma; target of Rs 625: ICICI Direct
ICICI Direct recommended hold rating on Alembic Pharma with a target price of Rs 625 in its research report dated November 14, 2022. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
With reference to the captioned subject, please find enclosed herewith the intimation dated 20th November, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding receipt of the request(s)/application(s) from the registered shareholder(s) of the Company for issue of Duplicate Share Certificate(s). We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Nifedipine Extended-Release Tablets USP, 30 mg, 60 mg and 90 mg.